Document Detail

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
MedLine Citation:
PMID:  11692295     Owner:  NLM     Status:  MEDLINE    
Treatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are increasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response-activating compound, approved by the United States Food and Drug Administration, that is currently used to treat cervical warts and has been shown to activate macrophage killing of Leishmania species. Therefore, an open-label, prospective study was conducted of combined imiquimod plus meglumine antimonate therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to meglumine antimonate therapy. All of the patients responded well to this combination therapy, and 90% were found to be cured at the 6-month follow-up period.
I Arevalo; B Ward; R Miller; T C Meng; E Najar; E Alvarez; G Matlashewski; A Llanos-Cuentas
Related Documents :
17581685 - Effects of sodium valproate and carbamazepine on food competition aggression in pigeons.
11692295 - Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiq...
3162585 - Complement activation as a possible in vitro indication of the inflammatory potential o...
7189675 - Chronic lithium treatment and dopamine-mediated behavior.
3719405 - Burns caused by flaming foods and drinks.
18239985 - Gastrointestinal motility in acute illness.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2001-10-23
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  33     ISSN:  1537-6591     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-11-05     Completed Date:  2001-12-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1847-51     Citation Subset:  IM    
Department of Microbiology and Immunology, McGill University, and Department of Tropical Medicine, McGill University Hospital Complex, Montreal, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use*
Aminoquinolines / therapeutic use*
Antiprotozoal Agents / therapeutic use*
Child, Preschool
Drug Resistance*
Drug Therapy, Combination
Leishmaniasis, Cutaneous / drug therapy*,  pathology
Meglumine / therapeutic use*
Middle Aged
Organometallic Compounds / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Aminoquinolines; 0/Antiprotozoal Agents; 0/Organometallic Compounds; 133-51-7/meglumine antimoniate; 6284-40-8/Meglumine; 99011-02-6/imiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospir...
Next Document:  Enzyme immunoassay for the diagnosis of cat-scratch disease defined by polymerase chain reaction.